Vismodegib [ERIVEDGE]

Abbreviation
NA
Disease(s)
Basal cell carcinoma (Skin Cancer)
Background
.pdf
Patent oppositions filed in
India

Vismodebig is a molecular inhibitor of Hedgehog signaling pathway and approved for use in the treatment of metastatic and locally advanced basal cell carcinoma (BCC).

This drug is missing the following documents, can you help us by contributing something?

Oppositions

Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
India30-06-2017Cancer Patient Aid Association (CPAA)Pre-GrantGrantedMolecules2007/DELNP/2007View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top